In an Investors Business Daily article last week entitled, “Dauntless Jeffrey Gottfurcht Beats Mountainous Odds,”  Jeff was featured for his Mount Everest climb and his use of Nyloxin™ to treat the pain and inflammation from his rheumatoid arthritis.  The article is both online and in print.

Jeff Gottfurcht and his Sherpa Danuru at 29,035 feet on the summit of Everest

 

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma and Nyloxin™ in Investors Business Daily", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

During her sophomore year of high school, Jessi was diagnosed with juvenile arthritis (JA). Due to the severity of her illness, she had to endure chemotherapy treatments and lengthy hospital stays. Her dream to go to college seemed like it would never come true. But Jessi persevered; she would not allow her condition to prevent her from getting a college education. She applied to Boise State University and was elated the day she found out she was accepted.

However, getting accepted was only the first step. With the high cost of college and being an out-of-state student, the Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF) stepped in to help. “We wanted Jessi to be able to focus on school and the college experience and not have to get a job,” commented Jeff Gottfurcht, founder of the organization.  ”It was the pleasure of the entire JFCAF team to help Jessi realize her dream.”

Leaving California for the first time in her life, and beginning this new journey is an extra special experience for Jessi, as her challenges are unique to most college bound students. “It is an honor for us to have the resources to help Jessi further her education and allow her the opportunity to get her degree,” said Jeff. “This is a dream that will truly last forever, and that’s what our organization is all about – changing the lives of families with children who have arthritis.”

Jeff Gottfurcht and Jessi celebrate the power of Nyloxin™ and Nutra Pharma’s ongoing support of Juvenile Arthritis

 

Jeff and Jessi along with JGCAF Dream Board member and RA sufferer Karen Ager

Everyone here at Nutra Pharma Corp. wishes Jessi good health and the best of luck in her college adventure.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Jeffrey Gottfurcht Children’s Arthritis Fund Making Dreams Come True for Children with Arthritis", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Nutra Pharma has received approval in India for its Nyloxin™ line of pain relievers.  The Company has also accepted orders for immediate distribution from India-based importers to support the launch, marketing and sales of Nyloxin™ throughout India…Please click here to read the rest of story.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma to Market Nyloxin™ in India", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

A recent article published in the Journal of Pain Research, indicates that regular practice of yoga may decrease pain in women with fibromyalgia.

Fibromyalgia is a chronic disease causing muscle, connective tissue and joint pain and fatigue. It is also known that fibromyalgia sufferers produce insufficient amounts of cortisol, a natural steroid in the body that helps to fight inflammation. In 2004, the American College of Rheumatology reported that approximately one in 50 Americans has fibromyalgia, and that between 80 and 90 percent of those who suffer from the disease are women.

Unfortunately there are no specific tests to determine if a patient has fibromyalgia. And because the symptoms are similar to many other serious illnesses, the disease is often misdiagnosed.

The recent study posted in the Journal of Pain Research was conducted by the Psychology Department at York University in Toronto, Canada. 22 women with fibromyalgia were asked to take 75-minute Hatha yoga classes twice per week for 8 consecutive weeks. Hatha practice was chosen because it is a more gentle form of yoga, which can be modified to accommodate physical limitations, such as those that may occur from fibromyalgia pain. Classes included a variety of postures, breathing exercises and a brief meditation.

Participants were given questionnaires about their levels of pain before, during and after the study, and salivary samples of cortisol were collected 3 times per day for each participant for 2 days before and after the study. In addition, participants were asked to keep a journal of their physical and emotional experiences throughout the study.

The results of the study showed an improvement in all levels of pain as well as psychological variables including pain acceptance, feelings of helplessness and mindfulness. Most importantly, cortisol levels increased significantly during the 8-week yoga practice. An increase in cortisol improves the body’s ability to reduce the inflammation that causes pain. This suggests that both the physical movements and mindfulness that comes with Hatha yoga practice benefit women who are suffering from fibromyalgia pain.

It would be beneficial for further studies to be conducted with a larger sampling of participants and longer period of yoga practice, to confirm the encouraging findings of this study. In the mean time, if you or someone you know has fibromyalgia, taking a yoga class might just be beneficial.

 

Curtis, K., Katz, J. & Osadchuk, A., (2011) An Eight-Week Yoga Intervention is Associated with Improvements in Pain, Psychological Functioning and Mindfulness, and Changes in Cortisol Levels in Women with Fibromyalgia. Journal of Pain Research, July 25, 2011 Vol. 2011:4 Pages 189 – 201.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " ", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

With over 23 million visitors each month, HealthCentral.com is one of the most popular health websites on the internet. Comprising of 35 sites that address the most common ailments, Health Central is stocked with detailed information about symptoms and treatment options for diseases and also offers forums and daily health blogs for readers.

Jeff Gottfurcht

This week, mountain climber, Jeffrey Gottfurcht, was interviewed on the Health Central Rheumatoid Arthritis site about his: struggle with RA; children’s charity; successful Mount Everest climb; and use of Nyloxin™.

You can read the interview here.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Jeff Gottfurcht Interview Published on Health Central Website", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.